1. Opening Hook
Just when everyone was busy debating pharma price erosion and China risk, Alivus Life Sciences quietly printed its highest-ever EBITDA margin. Not bad for a company that recently changed its name and ownership, but apparently kept its margin discipline intact.
From being a “Glenmark spin-off story” to now flexing 36%+ EBITDA margins, Q3FY26 felt less like a routine update and more like a subtle mic drop. CDMO doubled sequentially. Gross margins expanded 510 bps YoY. CAPEX got trimmed. Cash pile grew fatter.
And while management still chants “high single digit growth,” the subtext reads: capacity is ready, launches are lined up, and CDMO is warming up.
Read on. Because behind that calm tone lies a very deliberate playbook—and a few risks hiding in plain sight. Things get interesting. 😏
2. At a Glance
- Revenue ₹673 Cr – Highest ever, up 14.4% QoQ. Seasonality who?
- EBITDA ₹245 Cr – Margins at 36.4%. Record-breaking flex.
- Gross Margin 58.9% – Product mix doing heavy lifting.
- CDMO Revenue – Up 100% QoQ. From “wait and watch” to “watch this.”
- PAT ₹150 Cr – 22.3% margin. Clean and confident.
- Free Cash Flow ₹221 Cr (9M) – Cash machine humming.
- CAPEX Guidance Cut to ₹450 Cr – Spreadsheet discipline activated.
- Net Debt Free – ₹733 Cr cash. Dry powder ready.
3. Management’s Key Commentary
“We reported our highest ever revenue of ₹673 crores.”
(Translation: The name changed, but the growth engine didn’t.)
“EBITDA margin for the quarter was 36.4%, our highest ever reported quarterly margins.”
(Translation: We didn’t just recover post-PLI—we upgraded the operating model.) 😏
“CDMO revenue grew 100% QoQ and 85% YoY.”
(Translation: The ‘second half turnaround’
